The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

Mariana Lazo - One of the best experts on this subject based on the ideXlab platform.

  • Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad.
    Journal of epidemiology and global health, 2015
    Co-Authors: Rishi Ramtahal, Claude Khan, Kavita Maharaj-khan, Sriram Nallamothu, Avery Hinds, Andrew Dhanoo, Hsin-chieh Yeh, Felicia Hill-briggs, Mariana Lazo
    Abstract:

    The present study aims to determine the prevalence of self-reported sleep duration and sleep habits and their associated factors in patients with type 2 diabetes in Trinidad. This was a cross-sectional multicenter study. There were 291 patients with type 2 diabetes studied. Sleep habits were assessed using the Epworth Sleepiness Scale (ESS) and the National Health and Nutrition Examination Survey sleep disorder questionnaire. Demographic, anthropometric and biochemical data were also collected. The sample had a mean age of 58.8 years; 66.7% were female. The mean BMI was 28.9 kg/m(2). The prevalence of Excessive Daytime Sleepiness (EDS) was 11.3%. The prevalence of patients with short sleep (⩽6h) was 28.5%. The prevalence of patients with poor sleep was 63.9%. Poor sleep was associated with age, intensive anti-Diabetic Treatment and longer duration of diabetes. Short sleep was associated with intensive anti-Diabetic Treatment and BMI, while EDS was associated with increased BMI. In a sample of patients with type 2 diabetes, a high prevalence of self-reported sleep duration and unhealthy sleep habits was found. There needs to be an increased awareness of sleep conditions in adults with type 2 diabetes by doctors caring for these patients.

Clelia Volpe - One of the best experts on this subject based on the ideXlab platform.

  • tighter glycemic control is associated with adl physical dependency losses in older patients using sulfonylureas or mitiglinides results from the dimora study
    Metabolism-clinical and Experimental, 2015
    Co-Authors: Angela Marie Abbatecola, Fabio Armellini, Giovambattista Desideri, Paolo Falaschi, Antonio Greco, Gianbattista Guerrini, Fabrizia Lattanzio, Clelia Volpe, Ferdinando Damico, Giuseppe Paolisso
    Abstract:

    Abstract Background There is growing evidence that tight glycemic control may be more harmful than beneficial in older persons with Type 2 diabetes (T2DM). It remains controversial if tight glycemic control (lower glycated hemoglobin A1c (A1c)) is associated with functional impairments in older frail patients with T2DM. We explored associations between A1c and losses in Activities of Daily Living (ADLs) in Diabetic nursing home (NH) patients and tested for differences according to anti-Diabetic Treatment: diet, anti-Diabetic oral drug (AOD), insulin, combined insulin+AOD. Methods We conducted a cross-sectional study on 1845 older NH patients with T2DM from 150 sites across Italy. Complete evaluations on ADLs, glycemic control, anti-Diabetic Treatments, comorbidities, and clinical data were recorded. ANOVA was applied to compare clinical characteristics across A1c tertiles. Multivariate regression models evaluated associations between A1c and ADL losses. Results Patients had a mean age [SD]=82 [8] years; BMI=25.5kg/m 2 [4.7]; Fasting Plasma Glucose (FPG)=7.4 [3.0] mmol/l; Post-prandial glucose (PPG)=10.3 [3.6] mmol/l; A1c=7.0% (54mmol/mol), ADL losses=3.7 [1.8]. Compared to higher A1c tertiles, patients in the lower tertile had greater ADL losses, were more likely to use AODs, while less likely to use insulin or insulin+AOD. After adjusting for multiple confounders, impairments in ADLs were associated with tighter A1c levels ( B =−0.014; p=0.002). Regression models according to anti-Diabetic Treatment showed that tighter A1c levels continued as independent determinants of ADL losses in patients using AODs ( B =−0.023; p=0.001), particularly in those using sulfonylureas ( B =−0.043; p B =−0.044; p=0.050). Conclusions Tighter glycemic control was associated with ADL physical dependency losses, especially in those using sulfonylureas and mitiglinides.

  • Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: Results from the DIMORA study.
    Metabolism: clinical and experimental, 2015
    Co-Authors: Angela Marie Abbatecola, Fabio Armellini, Ferdinando D'amico, Giovambattista Desideri, Paolo Falaschi, Antonio Greco, Gianbattista Guerrini, Fabrizia Lattanzio, Clelia Volpe
    Abstract:

    There is growing evidence that tight glycemic control may be more harmful than beneficial in older persons with Type 2 diabetes (T2DM). It remains controversial if tight glycemic control (lower glycated hemoglobin A1c (A1c)) is associated with functional impairments in older frail patients with T2DM. We explored associations between A1c and losses in Activities of Daily Living (ADLs) in Diabetic nursing home (NH) patients and tested for differences according to anti-Diabetic Treatment: diet, anti-Diabetic oral drug (AOD), insulin, combined insulin+AOD. We conducted a cross-sectional study on 1845 older NH patients with T2DM from 150 sites across Italy. Complete evaluations on ADLs, glycemic control, anti-Diabetic Treatments, comorbidities, and clinical data were recorded. ANOVA was applied to compare clinical characteristics across A1c tertiles. Multivariate regression models evaluated associations between A1c and ADL losses. Patients had a mean age [SD]=82 [8] years; BMI=25.5 kg/m(2) [4.7]; Fasting Plasma Glucose (FPG)=7.4 [3.0] mmol/l; Post-prandial glucose (PPG)=10.3 [3.6] mmol/l; A1c=7.0% (54 mmol/mol), ADL losses=3.7 [1.8]. Compared to higher A1c tertiles, patients in the lower tertile had greater ADL losses, were more likely to use AODs, while less likely to use insulin or insulin+AOD. After adjusting for multiple confounders, impairments in ADLs were associated with tighter A1c levels (B=-0.014; p=0.002). Regression models according to anti-Diabetic Treatment showed that tighter A1c levels continued as independent determinants of ADL losses in patients using AODs (B=-0.023; p=0.001), particularly in those using sulfonylureas (B=-0.043; p<0.001) or mitiglinides (B=-0.044; p=0.050). Tighter glycemic control was associated with ADL physical dependency losses, especially in those using sulfonylureas and mitiglinides. Copyright © 2015 Elsevier Inc. All rights reserved.

Angela Marie Abbatecola - One of the best experts on this subject based on the ideXlab platform.

  • tighter glycemic control is associated with adl physical dependency losses in older patients using sulfonylureas or mitiglinides results from the dimora study
    Metabolism-clinical and Experimental, 2015
    Co-Authors: Angela Marie Abbatecola, Fabio Armellini, Giovambattista Desideri, Paolo Falaschi, Antonio Greco, Gianbattista Guerrini, Fabrizia Lattanzio, Clelia Volpe, Ferdinando Damico, Giuseppe Paolisso
    Abstract:

    Abstract Background There is growing evidence that tight glycemic control may be more harmful than beneficial in older persons with Type 2 diabetes (T2DM). It remains controversial if tight glycemic control (lower glycated hemoglobin A1c (A1c)) is associated with functional impairments in older frail patients with T2DM. We explored associations between A1c and losses in Activities of Daily Living (ADLs) in Diabetic nursing home (NH) patients and tested for differences according to anti-Diabetic Treatment: diet, anti-Diabetic oral drug (AOD), insulin, combined insulin+AOD. Methods We conducted a cross-sectional study on 1845 older NH patients with T2DM from 150 sites across Italy. Complete evaluations on ADLs, glycemic control, anti-Diabetic Treatments, comorbidities, and clinical data were recorded. ANOVA was applied to compare clinical characteristics across A1c tertiles. Multivariate regression models evaluated associations between A1c and ADL losses. Results Patients had a mean age [SD]=82 [8] years; BMI=25.5kg/m 2 [4.7]; Fasting Plasma Glucose (FPG)=7.4 [3.0] mmol/l; Post-prandial glucose (PPG)=10.3 [3.6] mmol/l; A1c=7.0% (54mmol/mol), ADL losses=3.7 [1.8]. Compared to higher A1c tertiles, patients in the lower tertile had greater ADL losses, were more likely to use AODs, while less likely to use insulin or insulin+AOD. After adjusting for multiple confounders, impairments in ADLs were associated with tighter A1c levels ( B =−0.014; p=0.002). Regression models according to anti-Diabetic Treatment showed that tighter A1c levels continued as independent determinants of ADL losses in patients using AODs ( B =−0.023; p=0.001), particularly in those using sulfonylureas ( B =−0.043; p B =−0.044; p=0.050). Conclusions Tighter glycemic control was associated with ADL physical dependency losses, especially in those using sulfonylureas and mitiglinides.

  • Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: Results from the DIMORA study.
    Metabolism: clinical and experimental, 2015
    Co-Authors: Angela Marie Abbatecola, Fabio Armellini, Ferdinando D'amico, Giovambattista Desideri, Paolo Falaschi, Antonio Greco, Gianbattista Guerrini, Fabrizia Lattanzio, Clelia Volpe
    Abstract:

    There is growing evidence that tight glycemic control may be more harmful than beneficial in older persons with Type 2 diabetes (T2DM). It remains controversial if tight glycemic control (lower glycated hemoglobin A1c (A1c)) is associated with functional impairments in older frail patients with T2DM. We explored associations between A1c and losses in Activities of Daily Living (ADLs) in Diabetic nursing home (NH) patients and tested for differences according to anti-Diabetic Treatment: diet, anti-Diabetic oral drug (AOD), insulin, combined insulin+AOD. We conducted a cross-sectional study on 1845 older NH patients with T2DM from 150 sites across Italy. Complete evaluations on ADLs, glycemic control, anti-Diabetic Treatments, comorbidities, and clinical data were recorded. ANOVA was applied to compare clinical characteristics across A1c tertiles. Multivariate regression models evaluated associations between A1c and ADL losses. Patients had a mean age [SD]=82 [8] years; BMI=25.5 kg/m(2) [4.7]; Fasting Plasma Glucose (FPG)=7.4 [3.0] mmol/l; Post-prandial glucose (PPG)=10.3 [3.6] mmol/l; A1c=7.0% (54 mmol/mol), ADL losses=3.7 [1.8]. Compared to higher A1c tertiles, patients in the lower tertile had greater ADL losses, were more likely to use AODs, while less likely to use insulin or insulin+AOD. After adjusting for multiple confounders, impairments in ADLs were associated with tighter A1c levels (B=-0.014; p=0.002). Regression models according to anti-Diabetic Treatment showed that tighter A1c levels continued as independent determinants of ADL losses in patients using AODs (B=-0.023; p=0.001), particularly in those using sulfonylureas (B=-0.043; p<0.001) or mitiglinides (B=-0.044; p=0.050). Tighter glycemic control was associated with ADL physical dependency losses, especially in those using sulfonylureas and mitiglinides. Copyright © 2015 Elsevier Inc. All rights reserved.

Rishi Ramtahal - One of the best experts on this subject based on the ideXlab platform.

  • Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad.
    Journal of epidemiology and global health, 2015
    Co-Authors: Rishi Ramtahal, Claude Khan, Kavita Maharaj-khan, Sriram Nallamothu, Avery Hinds, Andrew Dhanoo, Hsin-chieh Yeh, Felicia Hill-briggs, Mariana Lazo
    Abstract:

    The present study aims to determine the prevalence of self-reported sleep duration and sleep habits and their associated factors in patients with type 2 diabetes in Trinidad. This was a cross-sectional multicenter study. There were 291 patients with type 2 diabetes studied. Sleep habits were assessed using the Epworth Sleepiness Scale (ESS) and the National Health and Nutrition Examination Survey sleep disorder questionnaire. Demographic, anthropometric and biochemical data were also collected. The sample had a mean age of 58.8 years; 66.7% were female. The mean BMI was 28.9 kg/m(2). The prevalence of Excessive Daytime Sleepiness (EDS) was 11.3%. The prevalence of patients with short sleep (⩽6h) was 28.5%. The prevalence of patients with poor sleep was 63.9%. Poor sleep was associated with age, intensive anti-Diabetic Treatment and longer duration of diabetes. Short sleep was associated with intensive anti-Diabetic Treatment and BMI, while EDS was associated with increased BMI. In a sample of patients with type 2 diabetes, a high prevalence of self-reported sleep duration and unhealthy sleep habits was found. There needs to be an increased awareness of sleep conditions in adults with type 2 diabetes by doctors caring for these patients.

Buket Demirci - One of the best experts on this subject based on the ideXlab platform.

  • The effects of dexpanthenol in streptozotocin-induced Diabetic rats: histological, histochemical and immunological evidences.
    Histology and Histopathology, 2014
    Co-Authors: Kanat Gulle, N.g. Ceri, Meryem Akpolat, Mehmet Arasli, Buket Demirci
    Abstract:

    This study was designed to investigate the effects of Dexpanthenol (Dxp) on liver and pancreas histology and cytokine levels in streptozotocine (STZ)-induced Diabetic rats. Twenty-four Wistar albino male rats were divided into four groups: control, Dxp, STZ-induced Diabetic (STZ) and Diabetic Treatment with Dexpanthenol (STZ-Dxp) groups. Experimental diabetes was induced by single dose STZ (50 mg/kg) intraperitoneally (i.p.). After administration of STZ, the STZ-Dxp group began to receive a 300 mg/kg/day i.p. dose of Dxp for 6 weeks. Liver and pancreas tissues of the control group were in normal morphology. Liver tissue of STZ group showed vacuolisation of hepatocytes in the liver parenchyma with enlargement of sinusoidal spaces and increasing amounts of connective tissue in the portal area. Pancreatic section of STZ group displayed s-cells with of cytoplasmic mass, reduction of islet size, and atrophy. The STZ-Dxp group that received Dxp Treatment exhibit partially normal hepatic parenchyma. Histochemical examinations revealed that the diabetes-induced glycogen depletion markedly improved with the Dxp Treatment (p